Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Relmada Therapeutics Inc (NQ: RLMD ) 3.000 +0.010 (+0.33%) Streaming Delayed Price Updated: 1:19 PM EDT, Jun 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Relmada Therapeutics Inc < Previous 1 2 3 4 Next > Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday June 05, 2024 Via Benzinga 7 Penny Biotech Stocks to Triple Your Investment May 28, 2024 Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. Via InvestorPlace RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024 May 08, 2024 RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023 March 19, 2024 RLMD stock results show that Relmada Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Recap: Relmada Therapeutics Q4 Earnings March 19, 2024 Via Benzinga Earnings Scheduled For March 19, 2024 March 19, 2024 Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. Via Benzinga Earnings Outlook For Relmada Therapeutics March 18, 2024 Via Benzinga Earnings Outlook For Relmada Therapeutics November 07, 2023 Via Benzinga Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying February 01, 2024 The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... Via Benzinga Topics Stocks Exposures US Equities Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 04, 2024 Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 04, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday October 04, 2023 We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. Via InvestorPlace 12 Health Care Stocks Moving In Thursday's Pre-Market Session September 21, 2023 Via Benzinga Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study September 20, 2023 Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3... Via Benzinga Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm August 11, 2023 From Bragar Eagel & Squire Via GlobeNewswire FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says August 07, 2023 Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million. Via Benzinga Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm August 06, 2023 From Bragar Eagel & Squire Via GlobeNewswire 7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick July 31, 2023 For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly. Via InvestorPlace Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm July 26, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm July 21, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm July 16, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm July 10, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm July 05, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm July 01, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm June 25, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm June 19, 2023 From Bragar Eagel & Squire Via GlobeNewswire RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD June 10, 2023 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm June 04, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm May 19, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm May 14, 2023 From Bragar Eagel & Squire Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.